Narrow Therapeutics Need To Be Identified in Phase II - AAPS Workshop
Executive Summary
Narrow therapeutic index products need to be identified during Phase II clinical studies, Center for Drug Evaluation & Research Deputy Director for Pharmaceutical Science Roger Williams, MD, suggested March 18.